全文获取类型
收费全文 | 7316篇 |
免费 | 814篇 |
国内免费 | 179篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 57篇 |
妇产科学 | 29篇 |
基础医学 | 917篇 |
口腔科学 | 71篇 |
临床医学 | 298篇 |
内科学 | 245篇 |
皮肤病学 | 1910篇 |
神经病学 | 63篇 |
特种医学 | 140篇 |
外科学 | 479篇 |
综合类 | 438篇 |
现状与发展 | 1篇 |
预防医学 | 108篇 |
眼科学 | 578篇 |
药学 | 376篇 |
中国医学 | 77篇 |
肿瘤学 | 2441篇 |
出版年
2024年 | 25篇 |
2023年 | 153篇 |
2022年 | 241篇 |
2021年 | 292篇 |
2020年 | 322篇 |
2019年 | 339篇 |
2018年 | 284篇 |
2017年 | 302篇 |
2016年 | 278篇 |
2015年 | 383篇 |
2014年 | 391篇 |
2013年 | 556篇 |
2012年 | 352篇 |
2011年 | 341篇 |
2010年 | 299篇 |
2009年 | 292篇 |
2008年 | 307篇 |
2007年 | 313篇 |
2006年 | 275篇 |
2005年 | 308篇 |
2004年 | 254篇 |
2003年 | 226篇 |
2002年 | 200篇 |
2001年 | 178篇 |
2000年 | 149篇 |
1999年 | 145篇 |
1998年 | 116篇 |
1997年 | 112篇 |
1996年 | 86篇 |
1995年 | 75篇 |
1994年 | 59篇 |
1993年 | 83篇 |
1992年 | 57篇 |
1991年 | 60篇 |
1990年 | 46篇 |
1989年 | 43篇 |
1988年 | 38篇 |
1987年 | 44篇 |
1986年 | 25篇 |
1985年 | 43篇 |
1984年 | 40篇 |
1983年 | 26篇 |
1982年 | 20篇 |
1981年 | 31篇 |
1980年 | 33篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1972年 | 24篇 |
排序方式: 共有8309条查询结果,搜索用时 15 毫秒
1.
《中国现代医生》2020,58(8):65-67
目的 研究大剂量干扰素辅助治疗口腔黏膜恶性黑色素瘤的临床效果,探讨治疗应用的安全性。方法 选取我院于2017年11月~2018年11月收治的80例口腔黏膜恶性黑色素瘤患者作为研究对象,按照治疗方法不同分为两组,每组40例。对照组患者仅采用单纯手术治疗,治疗组在此基础上采用大剂量干扰素辅助治疗。观察两组患者生存情况、疾病复发情况以及毒副反应。结果 治疗组患者生存期限及无复发生存期明显长于对照组,治疗组复发率为5.00%,明显低于对照组的22.50%,差异有统计学意义(P0.05)。两组患者毒副反应比较差异无统计学意义(P0.05)。结论 口腔黏膜恶性黑色素瘤患者予以大剂量干扰素辅助疗法安全有效,值得临床推广。 相似文献
2.
3.
Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute 下载免费PDF全文
Masaki Otsuka Osamu Yamasaki Tatsuya Kaji Keiji Iwatsuki Kenji Asagoe 《The Journal of dermatology》2015,42(10):954-961
Sentinel lymph node biopsy (SLNB) is a widely accepted standard procedure for patients with clinically localized melanoma. Melanoma prevalence and Clark's subtype differ between Asians and Caucasians. Here, we evaluated our experience on SLNB for cutaneous melanoma in a Japanese population. SLNB was performed for patients with melanoma between July 2000 and June 2014. We retrospectively analyzed 102 patients regarding association of clinicopathological features with sentinel lymph node (SLN) status, melanoma‐specific survival (MSS) and disease‐free survival (DFS). A positive SLN was significantly associated with primary Breslow thickness. Compared with 43 patients with negative SLN, 59 patients with positive SLN had significantly shorter MSS (5‐year survival rate, 94.3% vs 63.2%; P = 0.0002) and DFS (5‐year survival rate, 92.7% vs 63.4%; P = 0.0004). According to our subgroup analyses, nine patients with positive non‐SLN had significantly shorter MSS compared with 32 patients with negative non‐SLN (5‐year survival rate, 32.4% vs 68.5%; P = 0.0273). The survival of 51 Japanese patients with acral lentiginous melanoma (ALM) was not inferior to the survival of patients with other Clark's subtype. Breslow thickness is an important factor for both MSS and DFS, and the status of SLN is the most predictive prognostic factor in Japanese patients with clinically localized melanomas, as in case of Caucasians. Features of ALM may be different between Asians and Caucasians. 相似文献
4.
5.
Melanoma is a deadly tumor, which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors. However, immunotherapy poses deleterious side effects and pursuit of new therapeutic targets is warranted. As knowledge of tumor immunology advances, such targets are being recognized. C-motif chemokine receptor-5 (CCR5) is a receptor found on immune cells whose effects impact the immune response both to induce inflammation and to activate suppressor cells causing an anti-inflammatory effect. CCR5 is well known as a target for HIV therapy where its blockade is efficient and safe, it is also known that its mutation CCR5delta32 is for the most part non-pathological to its carriers. In oncology, activation of the CCR5 receptor has been observed in high-stage disease and CCR5 blockade has been associated with an increased immune response. In this letter, we build up the rationale to utilize CCR5 as a therapeutic target for metastatic melanoma. 相似文献
6.
Taisuke Inada Satoshi Fukushima Masayuki Murai Masatoshi Jinnin Azusa Miyashita Satoshi Nakahara Junji Yamashita Jun Aoi Shinichi Masuguchi Hironobu Ihn 《The Journal of dermatology》2015,42(2):198-201
miRNA‐221 (miR‐221) is known to be abnormally expressed in many human cancers. The serum levels of miR‐221 have been reported as a tumor marker for malignant melanoma (MM). We hypothesized that the hair shaft miR‐221 levels may be increased in patients with MM. We therefore assessed the possibility that hair shaft miR‐221 levels could be a marker for MM. The hair shaft miR‐221 levels were significantly higher in patients with MM than controls. The rates of increased hair shaft miR‐221 levels above the cut‐off value were comparable to those of serum 5‐S‐CD, which is a tumor marker commonly used for MM. Measurements of the hair shaft miR‐221 levels could have potential clinical value in the detection of MM. This is the first report investigating the hair shaft levels of an miRNA in patients with MM. Our investigations offer new insight into the relationship between miR‐221 and MM, and may provide a new, non‐invasive way to screen for melanoma. 相似文献
7.
8.
9.
Sirt5 is known to functionally regulate mitochondrial proteins by altering posttranslational modifications, including lysine desuccinylation. While roles for Sirt5 as either a tumor promoter or suppressor, or in chemoresistance, have been implicated in other cancers, the function of Sirt5 in cutaneous melanoma has not been well examined. Therefore, to determine whether Sirt5 is necessary for BrafV600E‐mediated melanoma formation and/or disease progression, we crossed a genetically engineered murine melanoma model (TyrCreERT2/+; BrafLSL‐V600E/+; Ptenflox/flox) to Sirt5?/? knockout animals. In addition, we tested for synergism with a selective BRAF (V600E) inhibitor in Sirt5?/? mouse melanoma cells. Taken together, this report demonstrates that, in these models, Sirt5 is dispensable for BrafV600E‐mediated cutaneous melanoma formation and growth in vivo, and does not improve sensitivity to a selective BRAF inhibitor. 相似文献
10.
S Aquilina† M Dalmas‡ N Calleja§ P Gatt† L Scerri† 《Journal of the European Academy of Dermatology and Venereology》2006,20(8):958-963
BACKGROUND: The incidence of malignant melanoma of the skin has risen in every part of the world where reliable cancer registration data are found. OBJECTIVE: Our study aims to describe the changing incidence of and survival from invasive cutaneous malignant melanoma in Malta, by analysing the data from the 211 cases that were registered at the Malta National Cancer Registry between 1993 and 2002. RESULTS: The age standardized incidence rates for invasive cutaneous malignant melanoma rose from 3.7 per 100,000 population per year for males and 5.1 for females in the first 5-year period, to 8.0 per 100,000 population per year for males and 5.9 for females in the second 5-year period. In both sexes, numbers of thin (< or = 1.0 mm) invasive melanomas increased significantly between 1993 and 2002; males also registered a significant increase in intermediate-thickness (1.01-4.0 mm) melanomas. The increase in numbers of thin and intermediate-thickness melanomas between the two 5-year periods was greatest in patients aged 60 years and over. The overall absolute 5-year survival rate for the first period was 74% and for the second period 92%. CONCLUSION: Numbers of reported cases of invasive cutaneous malignant melanoma in Malta have more than doubled during the 10-year study period. This is mostly due to a marked rise in the diagnosis of thin melanomas in both sexes, occurring mainly in patients aged 60 years and over. As thin melanomas are of low metastasizing potential, this has resulted in an increase in survival between the two 5-year study periods. 相似文献